Pharma-Compintel

Turning Pharma Data into Strategic Decisions

Why use PCI ?

ABOUT PCI

What is Competitive Intelligence
in the Pharmaceutical Sector

Competitive Intelligence (CI) in the pharmaceutical sector refers to the systematic collection, analysis, and application of information about competitors, market dynamics, and industry trends to support strategic decision-making. It is a legal and ethical process that helps pharmaceutical companies anticipate market shifts, identify opportunities, and reduce business risks.

Licensing & M&A

CI supports business development by identifying promising licensing opportunities or acquisition targets early in the innovation cycle.

Commercial Strategy

CI helps in benchmarking sales force effectiveness, launch timing, promotional tactics, and patient support programs.

Market Access & Pricing

CI informs pricing strategies by analyzing reimbursement trends, payer preferences, and pricing models in different regions.

Regulatory Strategy

Understanding how competitors navigate regulatory pathways (e.g., accelerated approvals, orphan designations) allows companies to optimize their own submissions and market entry strategies

Pipeline Analysis

CI tracks competitors' drug development pipelines to forecast future market entries and therapeutic innovations. This includes monitoring clinical trial registries, scientific publications, regulatory filings (e.g., FDA or EMA), and patents.

Check what you
will get Here

OUR PROFILES

Choose your
Profile

Pharma Profile

Pharma Analysts using Competitive Intelligence win faster!

Pharmaceutical organizations using structured competitive intelligence achieve up to 34% faster R&D cycles compared with companies without systematic CI programs. Better intelligence → Better trial strategy → Faster development decisions. Market Access teams using competitive intelligence win earlier and price smarter! Pharmaceutical companies using advanced analytics and market intelligence for pricing and reimbursement achieve on average 12–18% higher net prices compared with companies relying on traditional approaches. Data-driven market access platforms integrating competitive intelligence can also produce 17% higher tender win rates and 9% margin expansion, demonstrating the commercial advantage of intelligence-driven pricing strategies. Better intelligence → Better payer strategy → Stronger pricing & faster access

Investor Profile

Data-driven investors outperform intuition!

Firms using data-driven decision making are 5–6% more productive and profitable than competitors relying mainly on intuition. Competitive intelligence + market analytics = smarter capital allocation

Public Profile

Evidence beats opinion!

Leaders and public decision-makers who rely on structured data analysis and evidence-based insights are up to 25% more likely to achieve successful policy or program outcomes, highlighting the advantage of systematic intelligence over opinion-driven decisions.

Investor Profile

Data-driven investors outperform intuition!

Public Sector

Evidence beats opinion!

CLIENT FEEDBACK

The portfolio what
we achieved

Pharma-CompIntel is a fantastic platform for anyone working in the pharmaceutical industry. The insights and competitive intelligence it provides make it much easier to track market trends and competitor activities. The interface is clean, and the data is very well organized.

Richard AndersonSeven Media - creative director

Pharma-CompIntel has transformed the way we track competitors and market trends. Their insights are clear, reliable, and have directly supported smarter strategic decisions.